228 related articles for article (PubMed ID: 25403591)
1. Designs of drug-combination phase I trials in oncology: a systematic review of the literature.
Riviere MK; Le Tourneau C; Paoletti X; Dubois F; Zohar S
Ann Oncol; 2015 Apr; 26(4):669-674. PubMed ID: 25403591
[TBL] [Abstract][Full Text] [Related]
2. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
3. Practical designs for Phase I combination studies in oncology.
Wages NA; Ivanova A; Marchenko O
J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
[TBL] [Abstract][Full Text] [Related]
4. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
[TBL] [Abstract][Full Text] [Related]
5. On the coherence of model-based dose-finding designs for drug combination trials.
Park Y; Liu S
PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
[TBL] [Abstract][Full Text] [Related]
6. dfcomb: An R-package for phase I/II trials of drug combinations.
Riviere MK; Jourdan JH; Zohar S
Comput Methods Programs Biomed; 2016 Mar; 125():117-33. PubMed ID: 26652977
[TBL] [Abstract][Full Text] [Related]
7. Accelerated titration designs for phase I clinical trials in oncology.
Simon R; Freidlin B; Rubinstein L; Arbuck SG; Collins J; Christian MC
J Natl Cancer Inst; 1997 Aug; 89(15):1138-47. PubMed ID: 9262252
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the implementation of novel designs for early-phase combination studies.
Wages NA; Conaway MR; Slingluff CL; Williams ME; Portell CA; Hwu P; Petroni GR
Ann Oncol; 2015 May; 26(5):1036-1037. PubMed ID: 25697216
[No Abstract] [Full Text] [Related]
10. Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C; Lee JJ; Siu LL
J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalation models for combination phase I trials in oncology.
Hamberg P; Ratain MJ; Lesaffre E; Verweij J
Eur J Cancer; 2010 Nov; 46(16):2870-8. PubMed ID: 20691584
[TBL] [Abstract][Full Text] [Related]
12. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
13. Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
Pierrillas PB; Fouliard S; Chenel M; Hooker AC; Friberg LE; Karlsson MO
AAPS J; 2018 Mar; 20(2):39. PubMed ID: 29516207
[TBL] [Abstract][Full Text] [Related]
14. Methodologic guidelines for the design of high-dose chemotherapy regimens.
Margolin K; Synold T; Longmate J; Doroshow JH
Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
[TBL] [Abstract][Full Text] [Related]
15. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
16. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.
Nikanjam M; Liu S; Yang J; Kurzrock R
Oncologist; 2017 May; 22(5):576-584. PubMed ID: 28424323
[TBL] [Abstract][Full Text] [Related]
17. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
Yada S; Hamada C
Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
[TBL] [Abstract][Full Text] [Related]
18. Optimal biological dose: a systematic review in cancer phase I clinical trials.
Fraisse J; Dinart D; Tosi D; Bellera C; Mollevi C
BMC Cancer; 2021 Jan; 21(1):60. PubMed ID: 33441097
[TBL] [Abstract][Full Text] [Related]
19. Adaptive designs for dual-agent phase I dose-escalation studies.
Harrington JA; Wheeler GM; Sweeting MJ; Mander AP; Jodrell DI
Nat Rev Clin Oncol; 2013 May; 10(5):277-88. PubMed ID: 23507740
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
